ASTRO/ASCO/AUA Guideline on Hypofractionation for Localized Prostate Cancer

Published: November 2018 (Web posted: October 2018)

Read Executive Summary
Read Full-Text Guideline

This guideline discusses how moderately hypofractionated and ultrahypofractionated schedules compare to conventional regimens in terms of prostate cancer control, toxicity and quality of life and the effect of patient and tumor factors on the appropriateness of hypofractionated radiation therapy. It also addresses appropriate dose-fractionation for both moderate and ultrahypofractionation. Additionally, normal tissue constraints and treatment volumes for hypofractionation and the role of image-guided and intensity-modulated radiation therapy in using these regimens were evaluated.

Developed in collaboration with:

• American Society for Radiation Oncology
• American Society for Clinical Oncology
• American Urologic Association

Endorsed by:

• European Society for Radiotherapy and Oncology
• The Royal Australian and New Zealand College of Radiologists
• Society of Urologic Oncology

Resources:
Implementation of Hypofractionated Prostate RT in the U.S.: A NCDB Analysis (CME)
Clinical Controversies (CME)
Podcast with Guideline Chairs 
Guideline Slide set
Patient Brochure